PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled,

BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance,

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus

BridgeBio Pharma NASDAQ: BBIO reported continued growth for its ATTR cardiomyopathy treatment Attrub

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.78) per share which missed the analy

Applied Materials, Coherent, CoreWeave and eight other names carry double-digit implied earnings mov

California State Teachers Retirement System boosted its stake in shares of BridgeBio Pharma, Inc. (N

PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

Additional FDA decisions could unlock new growth opportunities. Revenue is expected to nearly double

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earn

Affinity Asset Advisors LLC cut its stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 53.1

California Public Employees Retirement System raised its holdings in BridgeBio Pharma, Inc. (NASDAQ:

BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st

- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approv

Allspring Global Investments Holdings LLC cut its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO)

Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes e

Wall Street analysts change outlook on top names. Complete view of analyst rating changes including

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with

BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline prog

PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume

U.S. stocks higher, Nasdaq up 150+ points. Aehr Test Systems shares rose 13.6%. Other big gainers in

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's

Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%

BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates

BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to

BridgeBio Pharma BBIO has become a harder stock to judge after its sharp rare-disease run. Attruby i

BridgeBio Pharma shares Phase 3 trial update, but early data show progress for rare muscle disease t

BridgeBio stock rises after Phase 3 trial shows its drug helped children with achondroplasia grow fa

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped highe